Determinants of treatment outcomes for hepatitis c infection and the path to personalized medicine

Current Pharmacogenomics and Personalized Medicine

Volumn 9, Issue 2, 2011, Pages 123-136

  Kamal, Sanaa M ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Hepatitis c virus; Interleukin 28b polymorphisms; Pegylated interferon and ribavirin; Personalized medicine; Pharmacogenetics; Rational therapeutics

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR;

ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DRUG COST; EGYPT; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DISEASE; LIVER FIBROSIS; LIVER TRANSPLANTATION; MIXED INFECTION; NONHUMAN; PERSONALIZED MEDICINE; PHARMACOGENETICS; STEATOSIS; TREATMENT OUTCOME; VIRAL CLEARANCE;

HEPATITIS C VIRUS;

EID: 79955745332     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: 10.2174/187569211795508466     Document Type: Article

References (123)

1. World Health Organization. Hepatitis C. Geneva, Switzerland: World Health Organization; 2000.WHO fact sheet 164. Available at: http://www.who.int/mediacentre/factsheets/fs164/en/print.html. [Accessed March 13, 2011]
2. Armstrong GL, Wasley A, Simard EP, et al. The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through2002. Ann Intern Med 2006; 144(10): 705-14.
3. Desenclos JC. The challenge of hepatitis C surveillance in Europe. Euro surveil 2003; 8(5): 409.
4. Lavanchy D. The global burden of hepatitis C. Liver Int 2009;29(Suppl 1): 74-81.
5. Egyptian Ministry of Health Annual Report (2007) Available at: http://www.mohp.gov.eg/Main.asp. [Accessed March 13, 2011]
6. Lehman EM, Wilson ML. Epidemic hepatitis C virus infectionin Egypt: estimates of past incidence and future morbidity andmortality. J Viral Hepat 2009; 16(9): 650-8.
7. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: A systematic review of longitudinalstudies. J Viral Hepat 2006; 13: 34-41.
8. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 36: S21-9.
9. Seeff LB. The natural history of chronic hepatitis C virus infection. Clin Liver Dis 1997; 1(3): 587-602.
10. Santantonio T, Medda E, Ferrari C, et al. Risk factors and outcome among a large patient cohort with community-acquired acute hepatitisC in Italy. Clin Infect Dis 2006; 43: 1154-9.
11. Kamal SM, Ismail A, Graham CS, et al. Pegylated interferon atherapy in acute hepatitis C: Relation to hepatitis C virus specific Tcell response kinetics. Hepatology 2004; 39: 1721-31.
12. Kamal SM, Fouly AE, Kamel RR, et al. Peginterferon alfa-2btherapy in acute hepatitis C: Impact of onset of therapy onsustained virologic response. Gastroenterology 2006; 130: 632-8.
13. Kamal SM, Moustafa KN, Chen J, et al. Duration of peginterferontherapy in acute hepatitis C: A randomized trial. Hepatology 2006;43: 923-31.
14. Jonas MM. Children with hepatitis C. Hepatology 2002; 36(Suppl1): S173-8.
15. Bakr I, Rekacewicz C, El Hosseiny M, et al. Higher clearance ofhepatitis C virus infection in females compared with males. Gut 2006; 55: 1183-7.
16. Kamal SM, Amin A, Madwar M, et al. Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients. J Virol 2004; 78: 12252-8.
17. Farci P, Strazzera R, Alter HJ, et al. Early changes in hepatitis Cviral quasispecies during interferon therapy predict the therapeuticoutcome. Proc Natl Acad Sci USA 2002; 99: 3081-6.
18. Danta M, Brown D, Bhagani S, et al. HIV and Acute HCV.(HAAC) group. Recent epidemic of acute hepatitis C virus inHIV-positive men who have sex with men linked to high risk sexual behaviors. AIDS 2007; 21: 983-91.
19. Luetkemeyer A, Hare CB, Stansell J, et al. Clinical presentationand course of acute hepatitis C infection in HIV-infected patients. J Acquir Immune Defic Syndr 2006; 41: 31-6.
20. Angelico M, Renganathan E, Gandin C, et al. Chronic liver diseasein the Alexandria governorate, Egypt: contribution of schistosomiasisand hepatitis virus infections. J Hepatol 1997; 26(2): 236-43.
21. Kamal S, Madwar M, Bianchi L, et al. Clinical, virological andhistopathological features: long-term follow-up in patients withchronic hepatitis C co-infected with S. mansoni. Liver 2000; 20(4):281-9.
22. Kamal SM, Rasenack JW, Bianchi L, et al. Acute hepatitis C with out and with schistosomiasis: Correlation with hepatitis C-specificCD4(+) T-cell and cytokine response. Gastroenterology 2001; 121:646-56.
23. Kamal SM, Turner B, He Q, et al. Progression of fibrosis in hepatitisC with and without schistosomiasis: Correlation with serummarkers of fibrosis. Hepatology 2006; 43: 771-9.
24. Wells JT, Lucey MR, Said A. Hepatitis C in transplant recipients ofsolid organs, other than liver. Clin Liver Dis 2006; 10: 901-17.
25. Shoukry, NH, Cawthon AG, Walker CM. Cell-mediated immunityand the outcome of hepatitis C virus infection. Annu Rev Microbiol 2004; 58: 391-424.
26. Lechner F, Wong DK, Dunbar PR, et al. Analysis of successfulimmune responses in persons infected with hepatitis C virus. J ExpMed 2000; 191: 1499-1512.
27. Thimme R, Oldach D, Chang KM, et al. Determinants of viralclearance and persistence during acute hepatitis C virus infection. J Exp Med 2001; 194: 1395-1406.
28. Lechner F, Gruener NH, Urbani S, et al. CD8+ T lymphocyte responsesare induced during acute hepatitis C virus infection but arenot sustained. Eur J Immunol 2000; 30: 2479-87.
29. Khakoo SI, Thio CL, Martin MP, et al. HLA and NK cell inhibitoryreceptor genes in resolving hepatitis C virus infection. Science 2004; 305: 872-4.
30. An P, Thio CL, Kirk GD, et al. Regulatory polymorphisms in theinterleukin-18 promoter are associated with hepatitis C virus clearance. J Infect Dis 2008; 198(8): 1159-65.
31. Thio CL, Goedert JJ, Mosbruger T, et al. An analysis of tumornecrosis factor alpha gene polymorphisms and haplotypes withnatural clearance of hepatitis C virus infection. Genes Immun 2004;5: 294-300.
32. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28Band spontaneous clearance of hepatitis C virus. Nature 2009;461(7265): 798-801.
33. Rauch A, Kutalik Z, Descombes P. Genetic variation in IL28Bis associated with chronic hepatitis C and treatment failure: agenome-wide association study. Gastroenterology 2010; 138(4):1338-45.
34. Wiegand J, Buggisch P, Boecher W, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection:The HEP-NET acute-HCV-II study. Hepatology 2006; 43: 250-6.
35. De Rosa FG, Bargiacchi O, Audagnotto S, et al. Dose dependentand genotype-independent sustained virological response of a 12week pegylated interferon alpha-2b treatment for acute hepatitis C. J Antimicrob Chemother 2006; 57: 360-3.
36. Calleri G, Cariti G, Gaiottino F, et al. A short course of pegylatedinterferon-alpha in acute HCV hepatitis. J Viral Hepat 2007; 14:116-21.
37. De Rosa FG, Bargiacchi O, Audagnotto S, et al. Twelve weektreatment of acute hepatitis C virus with pegylated interferon- alpha-2b in injection drug users. Clin Infect Dis 2007; 45: 583-8.
38. Asselah T, Estrabaud E, Bieche I, et al. Hepatitis C: viral and hostfactors associated with non-response to pegylated interferon plusribavirin. Liver Int 2010; 30(9): 1259-69.
39. Lo Re, Amorosa VK, Localio AR, et al. Adherence to hepatitis Cvirus therapy and early virologic outcomes. Clin Infect Dis 2009;48(2): 186-93.
40. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b andribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl JMed 2005; 352(25): 2609-17.
41. Shiffman ML, Suter F, Bacon BR et al. Peginterferon alfa-2a andribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 124-34.
42. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2aplus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
43. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin forinitial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
44. Hasan F, Asker H, Al-Khaldi J, et al. Peginterferon alfa-2b plusribavirin for the treatment of chronic hepatitis C genotype 4. Am JGastroenterol 2004; 99: 1733-7.
45. Diago M, Hassanein T, Rodes J, et al. Optimized virologic responsein hepatitis C virus genotype 4 with peginterferon-alpha2aand ribavirin. Ann Intern Med 2004; 140: 72-3.
46. Kamal SM, El Tawil AA, Nakano T, et al. Peginterferon alpha-2band ribavirin therapy in chronic hepatitis C genotype 4: impact oftreatment duration and viral kinetics on sustained virological response.Gut 2005; 54: 858-66.
47. Zayadi A-R, Attia M, Barakat EM, et al. Response of hepatitis Cgenotype-4 naive patients to 24 weeks of peg-interferona2b/ribavirin or induction-dose interferon-a2b/ribavirin/ amantadine:a non-randomized controlled study. Am J Gastroenterol 2005; 100: 2447-52.
48. Derbala MF, Al Kaabi SR, El Dweik NZ, et al. Treatment ofhepatitis C virus genotype 4 with peginterferon alfa-2α: impact ofbilharziasis and fibrosis stage. World J Gastroenterol 2006; 12:5692-8.
49. Kamal S, Kamary S, Shardell M, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C:the role of rapid and early virologic response. Hepatology 2007;46(6): 1732-40.
50. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2aand ribavirin for 24 weeks in hepatitis C type 1 and 4 patientswith rapid virological response. Gastroenterology 2008; 135(2):451-8.
51. Kamal S, Ahmed A, Mahmoud S, et al. Enhanced Efficacy ofPegylated interferon alfa-2a plus ribavirin over pegylated interferonalfa-2b plus ribavirin in the treatment of patients with chronichepatitis C genotype 4: A randomized trial and health-relatedquality of life analysis. Liver Int. 2011; 31(3): 401-11.
52. Jensen DM, Morgan TR, Marcellin P, et al. Early identificationof HCV genotype 1 patients responding to 24 weeks peginterferonalpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43: 954-60.
53. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatmentwith peginterferon alfa-2b plus ribavirin in patients with chronichepatitis C infected with genotype 1 and low pretreatment viremia.J Hepatol 2006; 44: 97-103.
54. Lukasiewicz E, Gorfine M, Freedman LS, et al. Prediction of nonSVR to therapy with pegylated interferon-alpha 2a and ribavirin inchronic hepatitis C genotype 1 patients after 4, 8 and 12 weeks oftreatment. J Viral Hepat 2010; 17: 345-51.
55. Adinolfi LE, Durante-Mangoni E, Zampino R, et al. Hepatitis Cvirus associated steatosis-pathogenic mechanisms and clinicalimplications. Aliment Pharmacol Ther 2005; 22: 52-5.
56. Patel K, Zekry A, McHutchison JG. Steatosis and chronic hepatitisC virus infection: mechanisms and significance. Clin Liv Dis 2005;9(3): 399-410.
57. Lonardo A, Loria P, Adinolfi LE, et al. Hepatitis C and steatosis: areappraisal. J Viral Hepat 2006; 13(2): 73-80.
58. Asselah T, Rubbia-Brandt L, Marcellin P, et al. Steatosis in chronichepatitis C: why does it really matter? Gut 2006; 55: 123-30.
59. Thomopoulos KC, Theocharis GJ, Tsamantas AC, et al. Liversteatosis is an independent risk factor for treatment failure in patientswith chronic hepatitis C. Eur J Gastroenterol Hepatol 2005;17(2): 149-53.
60. Satapathy SK, Lingisetty CS, Proper S, et al. Equally poor outcomesto pegylated interferon-based therapy in African Americansand Hispanics with chronic hepatitis C infection. J Clin Gastroenterol 2007; 44 (2): 140-145.
61. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b andribavirin for the treatment of chronic hepatitis C in blacks and nonhispanic whites. N Engl J Med 2004; 350: 2265-71.
62. Jeffers L, Cassidy W, Howell CD, et al. Peginterferon alfa-2a (40kd) and ribavirin for black American patients with chronic hepatitisC virus genotype 1. Hepatology 2004; 39: 1702-8.
63. Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon andRibavirin Treatment in African American and Caucasian AmericanPatients with Chronic Hepatitis C Genotype 1. Gastroenterology 2006; 31: 470-7.
64. Roulot D, Bourcier V, Grando V, et al. Epidemiological characteristicsand response to peginterferon plus ribavirin treatment ofhepatitis C virus genotype 4 infection. J Viral Hepat 2007; 14(7):460-7.
65. Moucari R, Ripault MP, Martinot-Peignoux M, et al. Insulin resistanceand geographical origin: major predictors of liver fibrosis andresponse to peginterferon and ribavirin in HCV-4. Gut 2009;58(12): 1662-9.
66. Afdhal NH, McHutchison JG, Zeuzem S, et al. Hepatitis C pharmacogenetics:State of the art in 2010. Hepatology 2011; 53(1):336-45.
67. Angrist M. Personal Genomics and the Future of American Medicine. Mol Diagn Ther 2010; 14(2): 67-72.
68. Ioannidis JP, Thomas G, Daly MJ. Validating, augmenting, andrefining genome-wide association signals. Nat Rev Genet. 2009;10(5): 318-29.
69. Ge D, Fellay J, Thompson A et al. Genetic variation in IL28Bpredicts hepatitis C treatment-induced viral clearance. Nature 2009;461, 399-401.
70. Tanaka, Y. Nishida N, Sugiyama M, et al. Genome-wideassociation of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nature Genet 2009; 41,1105-110.
71. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associatedwith response to chronic hepatitis C interferon-α and ribavirin therapy. Nature Genet 2009; 41: 1100-4.
72. Montes-Cano MA, Garcia-Lozano JR, Abad-Molina C, et al. Interleukin-28B genetic variants and hepatitis virus infection by differentviral genotypes. Hepatology 2010; 52: 33-7.
73. Tillmann HL, Thompson AJ, Patel K, et al. A polymorphism nearIL28B is associated with spontaneous clearance of acute hepatitis Cvirus and jaundice. Gastroenterology 2010; 139(5): 1586-92.
74. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28Bpolymorphism improves viral kinetics and is the strongest pretreatmentpredictor of sustained virologic response in genotype 1hepatitis C virus. Gastroenterology 2010; 139(1): 120-9.
75. Mangia A, Thompson AJ, Santoro R, et al. An IL28B polymorphismdetermines treatment response of hepatitis C virus genotype2 or 3 patients who do not achieve a rapid virologic response.Gastroenterology 2010; 139(3): 821-7.
76. Clausen LN, Weis N, Astvad K, et al. Interleukin-28B polymorphismsare associated with hepatitis C virus clearance and viralload in a HIV-1-infected cohort. J Viral Hepat 2011; 18(4): 66-74.
77. Stättermayer AF, Stauber R, Hofer H, et al. Impact of IL28B genotypeon the early and sustained virologic response in treatmentnaïvepatients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011; 9(4): 344-50.
78. Lotrich FE, Loftis JM, Ferrell R, et al. IL28B polymorphism isassociated with both side effects and clearance of hepatitis C duringinterferon-alpha therapy. J Interferon Cytokine Res 2010 [Epubahead of print].
79. Kurosaki M, Tanaka Y, Nishida N, et al. Pre-treatment predictionof response to pegylated interferon plus ribavirin for chronic hepatitisC using genetic polymorphism in IL28B and viral factors. J Hepatol 2010 [Epub ahead of print].
80. Hayes CN, Kobayashi M, Akuta N, et al. HCV substitutions andIL28B polymorphisms on outcome of peg-interferon plus ribavirincombination therapy. Gut 2011; 60(2): 261-7.
81. Grebely J, Petoumenos K, Hellard M, et al. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitisC virus infection. Hepatology 2010; 52(4): 1216-24.
82. McCarthy JJ, Li JH, Thompson A, et al. Replicated associationbetween an IL28B gene variant and a sustained response to pegylatedinterferon and ribavirin. Gastroenterology 2010; 138(7):2307-14.
83. Darling JM, Aerssens J, Fanning G, et al. Quantitation of pretreatmentserum interferon-γ-inducible protein-10 improves the predictivevalue of an IL28B gene polymorphism for hepatitis C treatmentresponse. Hepatology 2011; 53(1): 14-22.
84. Lagging M, Askarieh G, Negro F, et al. Response prediction inchronic hepatitis C by assessment of IP-10 and IL28B-related singlenucleotide polymorphisms. PLoS One 2011; 24; 6(2): 17232.
85. Ito K, Higami K, Masaki N, et al. The rs8099917 polymorphism,determined by a suitable genotyping method, is a better predictorfor response to pegylated Interferon-{alpha}/ribavirin therapy inJapanese patients than other SNPs associated with IL28B. J Clin Microbiol 2011 [Epub ahead of print].
86. Honda M, Sakai A, Yamashita T. Hepatic ISG expression is associatedwith genetic variation in interleukin 28B and the outcome ofIFN therapy for chronic hepatitis C. Gastroenterology 2010;139(2): 499-509.
87. Urban TJ, Thompson AJ, Bradrick SS. IL28B genotype is associatedwith differential expression of intrahepatic interferonstimulatedgenes in patients with chronic hepatitis C. Hepatology 2010; 52(6): 1888-96.
88. Sarrazin C, Susser S, Doehring A, et al. Importance of IL 28B genepolympriphisms in hepatitis C virus genotypes 2 and 3 infected patients. 2011; 54(3): 415-21.
89. Scherzer TM, Hofer H, Staettermayer AF et al. Early virologicresponse and IL28B polymorphisms in patients with chronic hepatitisC genotype 3 treated with peginterferon alfa-2a and ribavirin. J Hepatol 2010 [Epub ahead of print].
90. Kawaoka T, Hayes CN, Ohishi W, et al. Predictive value of theIL28B polymorphism on the effect of interferon therapy in chronichepatitis C patients with genotypes 2a and 2b. J Hepatol 2011;54(3): 408-14.
91. Moghaddam A, Melum E, Reinton N, et al. IL28B genetic variationand treatment response in patients with hepatitis C virus genotype3 infection. Hepatology. 2011; 53(3): 746-54.
92. Bochud PY, Bibert S, Negro F, et al. IL28B polymorphisms predictreduction of HCV RNA from the first day of therapy in chronichepatitis C. J Hepatol 2011 [Epub ahead of print].
93. Hsu CS, Hsu SJ, Chen HC et al. Association of IL28B gene variationswith mathematical modeling of viral kinetics in chronic hepatitisC patients with IFN plus ribavirin therapy. Proc Natl Acad Sci USA 201; 108(9): 3719-24.
94. Romero-Gomez M, Eslam M, Ruiz A, et al. Genes and hepatitis C:susceptibility, fibrosis progression and response to treatment. LiverInt 2011; 31(4): 443-60.
95. Cai T, Dufour JF, Muellhaupt B, et al. Viral genotype-specific roleof PNPLA3, PPARG, MTTP and IL28B in hepatitis C virusassociatedsteatosis. J Hepatol 2011 [Epub ahead of print].
96. De Araujo ES, Dahari H, Cotler SJ, et al. Pharmacodynamics ofPEG-IFN alpa-2a and HCV response as a function of IL-28Bpolymorphism in HIV/HCV coinfected patients. J Acquir ImmuneDefic Syndr 2010 [Epub ahead of print].
97. Rallon NI, Naggie S, Benito GM, et al. Association of a singlenucleotide polymorphism near the interleukin 28 B gene with responseto hepatitis C therapy in HIV hepatitis C virus coinfectedpatients. AIDS 2010; 24(8): 23-29.
98. Aparicio E, Parera M, Franco S, et al. IL 28B SNP rs8099917 isstrongly associated with pegylated interferon alpha and ribavirintherapy treatment failure in HCV/HIV I coinfected patients. PLoSone 2010; 5(10): 1-5.
99. Pineda JA, Caruz A, Rivero A, et al. Prediction of response topegylated interferon plus ribavirin by IL28B gene variation in patientscoinfected with HIV and hepatitis C virus. Clin Infect Dis 2010; 51(7): 788-95.
100. Nattermann J, Vogel M, Nischalke HD, et al. Genetic variation inIL28B and treatment-induced clearance of hepatitis C virus in HIVpositivepatients with acute and chronic hepatitis C. J Infect Dis 2011; 203(5): 595-601.
101. Labarga P, Soriano V, Caruz A, et al. Association between IL28Bgene polymorphisms and plasma HCV-RNA levels in HIV/HCVco-infected patients. AIDS 2011; 25(6): 761-6.
102. Moderano J, Neukam K, Rallón N. Modeling the probability ofsustained virological response to therapy with pegylated interferonplus ribavirin in patients coinfected with hepatitis C virus and HIV. Clin Infect Dis 2010; 51(10): 1209-16.
103. Fukahara T, Taketomi A, Motomura T et al. Variance in IL 28B inliver recipients and donors correlate with response to PEGInterferonand ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139(5): 1577-85.
104. Lange CM, Moradpour D, Doehring A. Impact of donor and recipientIL-28 B rs12979860 genotypes in hepatitis C virus liver graftreinfection. J Hepatol 2010 [Epub ahead of print].
105. Patel K, Lucas J, Thompson J, et al. High predictive accuracy of anunbiased proteomic profile for sustained virologic response inchronic hepatitis C patients. Hepatology 2011; 53(3): 736-55.
106. di Iulio J, Ciuffi A, Fitzmaurice K, et al. Estimating the net contributionof IL28B variation to spontaneous hepatitis C virus clearance.Hepatology 2011 [Epub ahead of print].
107. Akuta N, Suzuki F, Hirakawa M, et al. Amino acid substitution inhepatitis C virus core region and genetic variation near the interleukin28B gene predict viral response to telaprevir with peginterferonand ribavirin. Hepatology 2010; 52(2): 421-9.
108. Donnelly RP, Kotenko SV. Interferon-lambda: a new addition to anold family. J Interferon Cytokine Res 2010; 30(8): 555-64.
109. Li M, Liu X, Zhou Y, et al. Interferon-lambdas: the modulators ofantivirus, antitumor, and immune responses. J Leukoc Biol 2009;86: 23-32.
110. Siren J, Pirhonen J, Julkunen I, et al. IFN-alpha regulates TLRdependentgene expression of IFN-alpha, IFN-beta, IL-28, and IL-29. J Immunol 2005; 174: 1932-7.
111. Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and theirclass IL cytokine receptor IL-28R. Nat Immunol 2003; 4: 63-8.
112. Marcello T, Grakoui A, Barba-Spaeth G, et al. Interferons alphaand lambda inhibit hepatitis C virus replication with distinct signaltransduction and gene regulation kinetics. Gastroenterology 2006;131: 1887-98.
113. Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibitshepatitis B and C virus replication. J Virol 2005; 79: 3851-4.
114. Shah BB, Wong JB. The economics of hepatitis C virus. Clin LiverDis 2006; 10(4): 717-34.
115. Davis KL, Mitra D, Medjedovic J, et al. Direct economic burden ofchronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol 2011; 45(2): 17-24.
116. Davis GL, Albright JE, Cook SF, et al. Projecting future complicationsof chronic hepatitis C in the United States. Liver Transpl 2003; 9(4): 331-8.
117. USAID Egypt demographic and health survey 2008. Available at: http://dec.usaid.gov/index.cfm?p=search.getCitation&rec_no=155528. [Accessed: March 3, 2011]
118. Abdel Kader, G. Taking on hepatitis. Available at: http://weekly.ahram.org.eg/2008/892/li11.htm, 2008. [Accessed: March 13, 2011]
119. Castera L, Constant A, Bernard PH, et al. Lifestyle changes andbeliefs regarding disease severity in patients with chronic hepatitisC. J Viral Hepat 2006; 13(7): 482-8.
120. Younossi ZM, Boparai N, Price LL, et al. Health related quality oflife in chronic liver disease: the impact of type and severity of disease.Am J Gastroenterol 2001; 96: 2199-205.
121. Foster GR. Quality of life considerations for patients with chronichepatitis C. J Viral Hepat 2009; 16(9): 605-11.
122. Sassi, F. Setting priorities for the evaluation of health interventions:when theory does not meet practice. Health Policy 2003; 63(2):141-54.
123. Rossignol JF, Elfert A, El-Gohary Y, et al. Improved virologicresponse in chronic hepatitis C genotype 4 treated with nitazoxanide,peginterferon, and ribavirin. Gastroenterology 2009;136(3): 856-62.